nice_new_london_office_internal_3_web

NICE shoots down Dupixent for severe asthma

pharmafile | March 9, 2020 | News story | Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma 

NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 inhibitor Dupixent (dupilumab) in the treatment of severe asthma.

The indication specifically relates to patients with type 2 inflammation that does not respond adequately to the combination of high-dose inhaled corticosteroids and another maintenance therapy.

The decision was made despite data indicating the superiority of Dupixent, when combined with standard asthma treatment, compared to placebo in reducing exacerbation frequency and reliance on oral corticosteroids in this patient population.

Ultimately, this was due to cost estimates for use of the drug coming in at a level higher than NHS resources would support.

Patients in this target population often prove difficult to treat and are prone to hospitalisation when sudden exacerbations arise.

Matt Fellows

Related Content

NICE recommends migraine treatment for NHS use

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …

Sanofi shares phase 2b results for dermatitis treatment

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …

GSK’s Jemperli recommended by NICE for endometrial cancer treatment

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended …

Latest content